- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Retinal vein occlusion (RVO)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 712KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 407KB)
Faricimab – July 2024
Faricimab; Solution for intravitreal injection 28.8 mg in 0.24 mL (120 mg per mL); Vabysmo®
Last updated
30 May 2025